Results 41 to 50 of about 174,614 (242)

Vertical Membrane‐Free Organ‐on‐a‐Chip for High‐Throughput In Vitro Studies and Drug Screening

Advanced Materials Technologies, EarlyView.
This novel microfluidic organ‐on‐a‐chip (OoC) platform enables cost‐effective, high‐throughput in vitro modeling. With vertical compartmentalization and gravity‐driven flow, it eliminates porous membranes and external pumps. Successfully generating intestine, cartilage, and tendon models, this study demonstrates drug responses, including 5‐fluorouracil
Xavier Barceló, Pooya Azizian, Blanca del Pozo, Marta Olle‐Monge, Lourdes Gombau, Joan M. Cabot   +5 more
wiley   +1 more source

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review [PDF]

, 2018
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with ...
Biankin, Andrew V., Khachigian, Levon M., Parish, Christopher R., Sheahan, Anjali V.   +3 more
core   +1 more source

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer

Advanced Science, EarlyView.
Microsatellite‐stable (MSS) colorectal cancer (CRC) resists immunotherapy. PRMT5 inhibition enhances CPT‐11 sensitivity, inducing a PMS2‐deficient‐like state and cytosolic dsDNA release, which activates the cGAS‐STING pathway to promote anti‐tumor immunity. However, this combination therapy upregulates TIGIT expression on CD8+ T cells, and the addition
Jiang Zhu, Shenao Fu, Xi Zou, Hanjiang Zeng, Guangzu Cui, Yinghui Peng, Diya Tang, Fan Zhang, Hong Shen, Shan Zeng, Ying Han   +10 more
wiley   +1 more source

Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8‐AS1/GPX4 Axis in Intrahepatic Cholangiocarcinoma

Advanced Science, EarlyView.
PAX8‐AS1 drives chemoresistance in intrahepatic cholangiocarcinoma by activating NRF2‐mediated GPX4 transcription and stabilizing GPX4 mRNA via IGF2BP3. Targeting the PAX8‐AS1/GPX4 axis with a GPX4 inhibitor enhances the efficacy of gemcitabine and cisplatin in preclinical models, offering a promising strategy to overcome chemotherapy resistance in ...
Zhi‐Wen Chen, Ji‐Jun Shan, Mo Chen, Zong Wu, Yi‐Ming Zhao, Hong‐Xu Zhu, Xin Jin, Yi‐Xiu Wang, Yi‐Bin Wu, Zhen Xiang, Zhi‐Wen Ding, Zhen‐Hai Lin, Long‐Rong Wang, Lu Wang   +13 more
wiley   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer - Preliminary results [PDF]

, 2003
Background: The local recurrence rate of colorectal cancer has been significantly reduced due to the use of combined radiochemotherapy. Despite this improvement regarding locally advanced tumour recurrences, the treatment strategy for pre-treated ...
Abdel-Rahman, Sultan, Dühmke, Eckhart, Ertl-Wagner, Birgit, Issels, Rolf-Dieter, Krych, M., Pachmann, S., Schaffer, Moshe, Schaffer, Pamela Manuela   +7 more
core   +1 more source

Neoadjuvant Chemotherapy With Cisplatin Up‐Regulates GSDMD to Enhance Oral Squamous Cell Carcinoma Metastasis Through MMP14‐Mediated EMT Activation

Advanced Science, EarlyView.
Oral squamous cell carcinoma cells exhibit upregulated expression of GSDMD upon exposure to low‐dose cisplatin chemotherapy, which subsequently interacts with MMP14 through its N‐terminal domain, activating the epithelial‒mesenchymal transition (EMT) process and promoting the lymph node metastasis of oral squamous cell carcinoma.
Zixian Huang, Qiming Jiang, Qianyu Zhang, Nan Lu, Xi Rui, Rui Chen, Yan Wang, Yuepeng Wang, Xiaoding Xu, Zhiquan Huang   +9 more
wiley   +1 more source

Duration of adjuvant chemotherapy for stage III colon cancer [PDF]

, 2018
BACKGROUND Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer.
Andre, Thierry, Boukovinas, Ioannis, Grothey, Axel, Iveson, Timothy, Kerr, Rachel, Labianca, Roberto, Meyerhardt, Jeffrey A., Meyers, Jeffrey P., Niedzwiecki, Donna, Paul, James, Renfro, Lindsay A., Sargent, Daniel J., Saunders, Mark, Shi, Qian, Shields, Anthony F., Sobrero, Alberto F., Souglakos, John, Taieb, Julien, Torri, Valter, Vernerey, Dewi, Watanabe, Toshiaki, Yamanaka, Takeharu, Yoshino, Takayuki   +22 more
core   +1 more source

Neutrophil‐Mimicking Nanomedicine Eliminates Tumor Intracellular Bacteria and Enhances Chemotherapy on Liver Metastasis of Colorectal Cancer

Advanced Science, EarlyView.
Fusobacterium nucleatum (Fn) enrichment has been identified in colorectal cancer and its liver metastases. This study develops neutrophil‐mimicking nanoparticles with multiple targeting capabilities encapsulating metronidazole and oxaliplatin for antibacterial and anticancer purposes. This approach reverses the epithelial mesenchymal transition process
Yanan Niu, Xu Zhao, Yong Li, Xiaoya Ma, Weifeng Yang, Jie Ma, Wanglin Li, Wei Yuan   +7 more
wiley   +1 more source

Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments. [PDF]

, 2018
In this study we utilized data on patient responses to guided treatments, and we evaluated their benefit for a non-small cell lung cancer cohort. The recommended therapies used were predicted using tumor molecular profiles that involved a range of ...
Alifrangis, C, Belluz, LDB, Carter, P, Cereser, B, Chandrasinghe, P, Krell, J, Lim, E, Moderau, N, Poyia, F, Stebbing, J, Tabassum, N, Zhang, H   +11 more
core   +2 more sources